# A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome

Source: https://onco.cc/trials/nct05804669/  
OnCo record `nct05804669` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of atumelnant in pituitary tumours and pituitary carcinoma, run by Crinetics Pharmaceuticals Inc., active and no longer recruiting.

## Summary

A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome is a phase 1/2 interventional study registered as NCT05804669 by Crinetics Pharmaceuticals Inc., with 19 participants enrolled, started 2023-10-12 and due to reach its primary completion in 2026-10. Interventions recorded: atumelnant.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05804669
- Phase: 1/2
- Setting: A Phase 1b/2a Open-label Multiple-ascending Dose Exploratory Study of CRN04894 in ACTH-dependent Cushing's Syndrome (Cushing's Disease or Ectopic ACTH Syndrome)
- Sponsor: Crinetics Pharmaceuticals Inc.
- Enrolled: 19

## Sources

- ClinicalTrials.gov NCT05804669: https://clinicaltrials.gov/study/NCT05804669

## Connected records

- cancers: [Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma](https://onco.cc/cancers/pituitary-tumours/)
- companies: [Crinetics Pharmaceuticals](https://onco.cc/companies/crinetics-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/nct05804669.json